Autologous Cell Therapy Market Size

Autologous Cell Therapy Market Size

Autologous Cell Therapy Market size valued at USD 12.9 billion in 2022 and is estimated to grow at 11.6% CAGR from 2023 to 2032. Rising prevalence of chronic disease coupled with growing demand for personalized treatment is expected to boost the market growth. For instance, in 2018, Food and Drug Administration (FDA) approved the CAR T-cell therapy tisagenlecleucel (Kymriah) for adults with certain types of non-Hodgkin lymphoma, a second CAR T-cell therapy approved for lymphoma. Thus, growing demand and adoption of personalized autologous cell therapies such as CAR-T is set to boost the market size.

To get key market trends

  Download Free Sample

Autologous cell therapy is a novel therapeutic approach that uses an individual’s cells, that are cultured and expanded outside the patient’s body and reintroduced into the donor. It involves the collection, isolation, and manipulation of cells from the patient's body, typically from sources such as blood, bone marrow, or adipose tissue. This personalized treatment approach offers several advantages, including a reduced risk of immune rejection or adverse reactions, as the cells used are a genetic match to the patient.